You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCocaine
Accession NumberDB00907  (APRD00080)
TypeSmall Molecule
GroupsApproved, Illicit
DescriptionAn alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. Cocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake. [PubChem]
Structure
Thumb
Synonyms
(-)-Cocaine
(−)-cocaine
[1R-(Exo,exo)]-3-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylic acid, methyl ester
2-Methyl-3beta-hydroxy-1alphah,5alphah-tropane-2beta-carboxylate benzoate (ester)
Benzoylmethylecgonine
beta-Cocain
Cocain
Cocaina
Cocaine
Cocainum
Kokain
L-Cocain
L-Cocaine
Methyl [1R-(exo,exo)]-3-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate
Methyl benzoylecgonine
Neurocaine
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cocaine Hydrochloride Top Sol 40mg/mlliquid40 mgtopicalSandoz Canada Incorporated1992-12-31Not applicableCanada
Cocaine Hydrochloride Topical Sol 10%liquid100 mgtopicalSandoz Canada Incorporated1992-12-31Not applicableCanada
PMS-cocaine Hydrochloride Topical Sol 4%liquid40 mgtopicalPharmascience Inc1997-03-17Not applicableCanada
PMS-cocaine Hydrochloride Topical Sol 10%liquid100 mgtopicalPharmascience Inc1995-12-31Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cocaine Hydrochloridesolution40 mg/mLtopicalLannett Company, Inc.2008-12-01Not applicableUs
Cocaine Hydrochloridesolution100 mg/mLtopicalLannett Company, Inc.2008-12-01Not applicableUs
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Cocaine hydrochloride
ThumbNot applicableDBSALT001521
Categories
UNIII5Y540LHVR
CAS number50-36-2
WeightAverage: 303.3529
Monoisotopic: 303.147058165
Chemical FormulaC17H21NO4
InChI KeyInChIKey=ZPUCINDJVBIVPJ-LJISPDSOSA-N
InChI
InChI=1S/C17H21NO4/c1-18-12-8-9-13(18)15(17(20)21-2)14(10-12)22-16(19)11-6-4-3-5-7-11/h3-7,12-15H,8-10H2,1-2H3/t12-,13+,14-,15+/m0/s1
IUPAC Name
methyl (1R,2R,3S,5S)-3-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate
SMILES
[H][C@]12CC[C@]([H])([[email protected]]([[email protected]](C1)OC(=O)C1=CC=CC=C1)C(=O)OC)N2C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzoic acid esters. These are ester derivatives of benzoic acid.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzoic acids and derivatives
Direct ParentBenzoic acid esters
Alternative Parents
Substituents
  • Benzoate ester
  • Tropane alkaloid
  • Piperidinecarboxylic acid
  • Benzylether
  • Benzoyl
  • N-alkylpyrrolidine
  • Piperidine
  • Dicarboxylic acid or derivatives
  • Methyl ester
  • Pyrrolidine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Carboxylic acid ester
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the introduction of local (topical) anesthesia of accessible mucous membranes of the oral, laryngeal and nasal cavities.
PharmacodynamicsCocaine is a local anesthetic indicated for the introduction of local (topical) anesthesia of accessible mucous membranes of the oral, laryngeal and nasal cavities.
Mechanism of actionCocaine produces anesthesia by inhibiting excitation of nerve endings or by blocking conduction in peripheral nerves. This is achieved by reversibly binding to and inactivating sodium channels. Sodium influx through these channels is necessary for the depolarization of nerve cell membranes and subsequent propagation of impulses along the course of the nerve. Cocaine is the only local anesthetic with vasoconstrictive properties. This is a result of its blockade of norepinephrine reuptake in the autonomic nervous system. Cocaine binds differentially to the dopamine, serotonin, and norepinephrine transport proteins and directly prevents the re-uptake of dopamine, serotonin, and norepinephrine into pre-synaptic neurons. Its effect on dopamine levels is most responsible for the addictive property of cocaine.
Related Articles
AbsorptionCocaine is absorbed from all sites of application, including mucous membranes and gastrointestinal mucosa. By oral or intra-nasal route, 60 to 80% of cocaine is absorbed.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic. Cocaine is metabolized to benzoylecgonine and ecgonine methyl ester, which are both excreted in the urine. In the presence of alcohol, a further active metabolite, cocaethylene is formed, and is more toxic then cocaine itself.

SubstrateEnzymesProduct
Cocaine
norcocaineDetails
Cocaine
Not Available
BenzoylecgonineDetails
Cocaine
Not Available
CocaethyleneDetails
Route of eliminationNot Available
Half life1 hour
ClearanceNot Available
ToxicityIntense agitation, convulsions, hypertension, rhythm disturbance, coronary insufficiency, hyperthermia, rhabdomyolysis, and renal impairment. Oral mouse LD50 = 96 mg/kg
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Cocaine Action PathwayDrug actionSMP00395
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8644
Blood Brain Barrier+0.8805
Caco-2 permeable+0.7654
P-glycoprotein substrateSubstrate0.5
P-glycoprotein inhibitor IInhibitor0.8168
P-glycoprotein inhibitor IINon-inhibitor0.893
Renal organic cation transporterInhibitor0.6182
CYP450 2C9 substrateNon-substrate0.7897
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6856
CYP450 1A2 substrateNon-inhibitor0.8627
CYP450 2C9 inhibitorNon-inhibitor0.9341
CYP450 2D6 inhibitorNon-inhibitor0.5614
CYP450 2C19 inhibitorNon-inhibitor0.9383
CYP450 3A4 inhibitorNon-inhibitor0.9237
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9408
Ames testNon AMES toxic0.7437
CarcinogenicityNon-carcinogens0.9585
BiodegradationNot ready biodegradable0.5319
Rat acute toxicity2.6387 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8463
hERG inhibition (predictor II)Non-inhibitor0.8042
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Solutiontopical100 mg/mL
Solutiontopical40 mg/mL
Liquidtopical40 mg
Liquidtopical100 mg
Prices
Unit descriptionCostUnit
Cocaine hydrochloride powder68.44USD g
Cocaine 10% solution10.68USD ml
Cocaine 4% solution6.22USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point98 °CPhysProp
water solubility1800 mg/L (at 22 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.30HANSCH,C ET AL. (1995)
logS-2.23ADME Research, USCD
pKa8.61 (at 15 °C)MERCK INDEX (1996)
Predicted Properties
PropertyValueSource
Water Solubility5.03 mg/mLALOGPS
logP1.97ALOGPS
logP2.28ChemAxon
logS-1.8ALOGPS
pKa (Strongest Basic)8.85ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area55.84 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity81.16 m3·mol-1ChemAxon
Polarizability32.36 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (2.96 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Nobuyuki Shigetoh, Hiroshi Nakayama, Jinsei Miyazaki, Tadayasu Mitsumata, “Labelling colors for detecting cocaine or methamphetamine, method of preparing the same and detector for cocaine or methamphetamine.” U.S. Patent US5571727, issued October, 1981.

US5571727
General References
  1. Siegel RK, Elsohly MA, Plowman T, Rury PM, Jones RT: Cocaine in herbal tea. JAMA. 1986 Jan 3;255(1):40. [PubMed:3940302 ]
  2. Volkow ND, Wang GJ, Fischman MW, Foltin R, Fowler JS, Franceschi D, Franceschi M, Logan J, Gatley SJ, Wong C, Ding YS, Hitzemann R, Pappas N: Effects of route of administration on cocaine induced dopamine transporter blockade in the human brain. Life Sci. 2000 Aug 11;67(12):1507-15. [PubMed:10983846 ]
  3. Dimitrijevic N, Dzitoyeva S, Manev H: An automated assay of the behavioral effects of cocaine injections in adult Drosophila. J Neurosci Methods. 2004 Aug 30;137(2):181-4. [PubMed:15262059 ]
  4. Uz T, Akhisaroglu M, Ahmed R, Manev H: The pineal gland is critical for circadian Period1 expression in the striatum and for circadian cocaine sensitization in mice. Neuropsychopharmacology. 2003 Dec;28(12):2117-23. [PubMed:12865893 ]
  5. McClung CA, Sidiropoulou K, Vitaterna M, Takahashi JS, White FJ, Cooper DC, Nestler EJ: Regulation of dopaminergic transmission and cocaine reward by the Clock gene. Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9377-81. Epub 2005 Jun 20. [PubMed:15967985 ]
External Links
ATC CodesS01HA01N01BC01R02AD03S02DA02
AHFS Codes
  • 52:16.00
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (104 KB)
Interactions
Drug Interactions
Drug
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Cocaine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Cocaine is combined with 7-Nitroindazole.
AcepromazineThe risk or severity of adverse effects can be increased when Cocaine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Cocaine is combined with Aceprometazine.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Cocaine.
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Cocaine.
adipiplonThe risk or severity of adverse effects can be increased when Cocaine is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Cocaine is combined with Agomelatine.
AjmalineThe metabolism of Ajmaline can be decreased when combined with Cocaine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Cocaine is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Cocaine.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Cocaine.
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Cocaine.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Cocaine is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Cocaine.
AlprenololThe metabolism of Alprenolol can be decreased when combined with Cocaine.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Cocaine.
AmiodaroneThe metabolism of Cocaine can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Cocaine is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Cocaine is combined with Amitriptyline.
AmobarbitalThe risk or severity of adverse effects can be increased when Cocaine is combined with Amobarbital.
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Cocaine.
AmoxapineThe risk or severity of adverse effects can be increased when Cocaine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Cocaine is combined with Amperozide.
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Cocaine.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Cocaine.
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Cocaine.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Cocaine.
AprepitantThe serum concentration of Cocaine can be increased when it is combined with Aprepitant.
AprindineThe metabolism of Aprindine can be decreased when combined with Cocaine.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Cocaine.
AripiprazoleThe risk or severity of adverse effects can be increased when Cocaine is combined with Aripiprazole.
ArtemetherThe metabolism of Artemether can be decreased when combined with Cocaine.
ArticaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Cocaine is combined with Asenapine.
AstemizoleThe metabolism of Astemizole can be decreased when combined with Cocaine.
AtazanavirThe metabolism of Cocaine can be decreased when combined with Atazanavir.
AtomoxetineThe serum concentration of Atomoxetine can be increased when it is combined with Cocaine.
AtomoxetineThe metabolism of Cocaine can be decreased when combined with Atomoxetine.
AzaperoneThe risk or severity of adverse effects can be increased when Cocaine is combined with Azaperone.
AzelastineCocaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Cocaine.
BaclofenThe risk or severity of adverse effects can be increased when Cocaine is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Cocaine is combined with Barbital.
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Cocaine.
BenzocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Benzocaine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Cocaine is combined with Benzyl alcohol.
BepridilThe metabolism of Bepridil can be decreased when combined with Cocaine.
BetaxololThe metabolism of Betaxolol can be decreased when combined with Cocaine.
BexaroteneThe serum concentration of Cocaine can be decreased when it is combined with Bexarotene.
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Cocaine.
BoceprevirThe metabolism of Cocaine can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Cocaine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Cocaine can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Cocaine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Cocaine.
BrimonidineThe risk or severity of adverse effects can be increased when Cocaine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Cocaine is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Cocaine is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Cocaine is combined with Brotizolam.
BufuralolThe metabolism of Bufuralol can be decreased when combined with Cocaine.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Cocaine.
BuprenorphineThe risk or severity of adverse effects can be increased when Cocaine is combined with Buprenorphine.
BupropionThe metabolism of Bupropion can be decreased when combined with Cocaine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Cocaine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Cocaine.
ButacaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Cocaine is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Cocaine is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Cocaine is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Cocaine.
CaffeineThe metabolism of Caffeine can be decreased when combined with Cocaine.
CaptoprilThe metabolism of Captopril can be decreased when combined with Cocaine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Cocaine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Cocaine is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Cocaine is combined with Carfentanil.
CariprazineThe metabolism of Cariprazine can be decreased when combined with Cocaine.
CarisoprodolThe risk or severity of adverse effects can be increased when Cocaine is combined with Carisoprodol.
CarteololThe metabolism of Carteolol can be decreased when combined with Cocaine.
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Cocaine.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Cocaine.
CeritinibThe serum concentration of Cocaine can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Cocaine is combined with Cetirizine.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Cocaine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Cocaine is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Cocaine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Cocaine is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Chloroprocaine.
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Cocaine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Cocaine is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Cocaine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Cocaine is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Cocaine is combined with Chlorzoxazone.
CilostazolThe metabolism of Cilostazol can be decreased when combined with Cocaine.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Cocaine.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Cocaine.
CitalopramThe risk or severity of adverse effects can be increased when Cocaine is combined with Citalopram.
ClarithromycinThe metabolism of Cocaine can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Cocaine can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Cocaine is combined with Clemastine.
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Cocaine.
ClidiniumThe risk or severity of adverse effects can be increased when Cocaine is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Cocaine is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Cocaine is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Cocaine is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Cocaine is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Cocaine is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Cocaine.
ClotrimazoleThe metabolism of Cocaine can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Cocaine.
CobicistatThe metabolism of Cocaine can be decreased when combined with Cobicistat.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Cocaine.
ConivaptanThe serum concentration of Cocaine can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Cocaine can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Cocaine is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cocaine is combined with Cyclobenzaprine.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Cocaine.
CyclosporineThe metabolism of Cocaine can be decreased when combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Cocaine is combined with Cyproheptadine.
DabrafenibThe serum concentration of Cocaine can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Cocaine is combined with Dantrolene.
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Cocaine.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Cocaine.
DapoxetineThe risk or severity of adverse effects can be increased when Cocaine is combined with Dapoxetine.
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Cocaine.
DarunavirThe metabolism of Cocaine can be decreased when combined with Darunavir.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Cocaine.
DasatinibThe serum concentration of Cocaine can be increased when it is combined with Dasatinib.
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Cocaine.
DeferasiroxThe serum concentration of Cocaine can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Cocaine can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Cocaine is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Cocaine is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Cocaine is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Cocaine is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Cocaine is combined with Detomidine.
DexamethasoneThe serum concentration of Cocaine can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Cocaine is combined with Dexbrompheniramine.
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Cocaine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Cocaine.
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Cocaine.
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Cocaine.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Cocaine.
DextromoramideThe risk or severity of adverse effects can be increased when Cocaine is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Cocaine.
DezocineThe risk or severity of adverse effects can be increased when Cocaine is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Cocaine.
DifenoxinThe risk or severity of adverse effects can be increased when Cocaine is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Cocaine is combined with Dihydrocodeine.
DihydroergotamineThe metabolism of Cocaine can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Cocaine is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Cocaine is combined with Dihydromorphine.
DiltiazemThe metabolism of Cocaine can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Cocaine is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Cocaine is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Cocaine is combined with Diphenoxylate.
DolasetronThe metabolism of Dolasetron can be decreased when combined with Cocaine.
DomperidoneThe metabolism of Domperidone can be decreased when combined with Cocaine.
DonepezilThe metabolism of Donepezil can be decreased when combined with Cocaine.
DopamineThe metabolism of Dopamine can be decreased when combined with Cocaine.
DoramectinThe risk or severity of adverse effects can be increased when Cocaine is combined with Doramectin.
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Cocaine.
DoxepinThe risk or severity of adverse effects can be increased when Cocaine is combined with Doxepin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Cocaine.
DoxycyclineThe metabolism of Cocaine can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Cocaine.
DoxylamineThe risk or severity of adverse effects can be increased when Cocaine is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Cocaine is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Cocaine.
DronabinolCocaine may increase the tachycardic activities of Dronabinol.
DronedaroneThe metabolism of Cocaine can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Cocaine.
DrotebanolThe risk or severity of adverse effects can be increased when Cocaine is combined with Drotebanol.
DuloxetineThe serum concentration of Duloxetine can be increased when it is combined with Cocaine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Cocaine.
EcgonineThe risk or severity of adverse effects can be increased when Cocaine is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Cocaine is combined with ECGONINE METHYL ESTER.
EfavirenzThe serum concentration of Cocaine can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Cocaine is combined with Efavirenz.
EletriptanThe metabolism of Eletriptan can be decreased when combined with Cocaine.
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Cocaine.
EncainideThe metabolism of Encainide can be decreased when combined with Cocaine.
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Cocaine.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Cocaine.
EntacaponeThe risk or severity of adverse effects can be increased when Cocaine is combined with Entacapone.
EnzalutamideThe serum concentration of Cocaine can be decreased when it is combined with Enzalutamide.
EpinastineThe metabolism of Epinastine can be decreased when combined with Cocaine.
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Cocaine.
ErythromycinThe metabolism of Cocaine can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Cocaine is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Cocaine can be decreased when it is combined with Eslicarbazepine acetate.
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Cocaine.
EstazolamThe risk or severity of adverse effects can be increased when Cocaine is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Cocaine.
EthanolCocaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Cocaine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Cocaine.
EthosuximideThe risk or severity of adverse effects can be increased when Cocaine is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Cocaine is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Cocaine is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Cocaine is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Cocaine is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Cocaine is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Cocaine is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Cocaine.
EtoperidoneThe risk or severity of adverse effects can be increased when Cocaine is combined with Etoperidone.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Cocaine.
EtorphineThe risk or severity of adverse effects can be increased when Cocaine is combined with Etorphine.
EtravirineThe serum concentration of Cocaine can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Cocaine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Cocaine is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Cocaine is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Cocaine is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Cocaine.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Cocaine.
FexofenadineThe risk or severity of adverse effects can be increased when Cocaine is combined with Fexofenadine.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Cocaine.
FlecainideThe metabolism of Flecainide can be decreased when combined with Cocaine.
FlibanserinThe risk or severity of adverse effects can be increased when Cocaine is combined with Flibanserin.
FluconazoleThe metabolism of Cocaine can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Cocaine is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Cocaine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Cocaine is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Cocaine is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Cocaine.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Cocaine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Cocaine.
FluspirileneThe risk or severity of adverse effects can be increased when Cocaine is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Cocaine is combined with Fluticasone Propionate.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Cocaine.
FluvoxamineThe risk or severity of adverse effects can be increased when Cocaine is combined with Fluvoxamine.
FluvoxamineThe metabolism of Cocaine can be decreased when combined with Fluvoxamine.
FormoterolThe metabolism of Formoterol can be decreased when combined with Cocaine.
FosamprenavirThe metabolism of Cocaine can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Cocaine can be increased when it is combined with Fosaprepitant.
FosphenytoinThe risk or severity of adverse effects can be increased when Cocaine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Cocaine is combined with Fospropofol.
Fusidic AcidThe serum concentration of Cocaine can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Cocaine is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Cocaine is combined with gabapentin enacarbil.
GalantamineThe metabolism of Galantamine can be decreased when combined with Cocaine.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Cocaine is combined with Gamma Hydroxybutyric Acid.
GefitinibThe metabolism of Gefitinib can be decreased when combined with Cocaine.
GlutethimideThe risk or severity of adverse effects can be increased when Cocaine is combined with Glutethimide.
GranisetronThe metabolism of Granisetron can be decreased when combined with Cocaine.
GuanfacineThe risk or severity of adverse effects can be increased when Cocaine is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Cocaine.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Cocaine.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Cocaine.
HalothaneThe risk or severity of adverse effects can be increased when Cocaine is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Cocaine is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Cocaine is combined with Hexobarbital.
HyaluronidaseThe risk or severity of adverse effects can be increased when Hyaluronidase is combined with Cocaine.
HydrocodoneThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Cocaine resulting in a loss in efficacy.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Cocaine.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Cocaine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Cocaine.
HydroxyzineThe risk or severity of adverse effects can be increased when Cocaine is combined with Hydroxyzine.
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Cocaine.
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Cocaine.
IdelalisibThe serum concentration of Cocaine can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Cocaine is combined with Iloperidone.
ImatinibThe metabolism of Cocaine can be decreased when combined with Imatinib.
ImipramineThe risk or severity of adverse effects can be increased when Cocaine is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Cocaine is combined with Indalpine.
IndinavirThe metabolism of Cocaine can be decreased when combined with Indinavir.
Ioflupane I-123Cocaine may decrease effectiveness of Ioflupane I 123 as a diagnostic agent.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Cocaine.
IsavuconazoniumThe metabolism of Cocaine can be decreased when combined with Isavuconazonium.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Cocaine.
IsradipineThe metabolism of Cocaine can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Cocaine can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Cocaine can be increased when it is combined with Ivacaftor.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Cocaine.
KetamineThe risk or severity of adverse effects can be increased when Cocaine is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Cocaine is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Cocaine is combined with Ketobemidone.
KetoconazoleThe metabolism of Cocaine can be decreased when combined with Ketoconazole.
LabetalolThe metabolism of Labetalol can be decreased when combined with Cocaine.
LamotrigineThe risk or severity of adverse effects can be increased when Cocaine is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Cocaine is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Cocaine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Cocaine is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Cocaine is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Cocaine is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Cocaine is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Cocaine.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Cocaine.
LisurideThe metabolism of Lisuride can be decreased when combined with Cocaine.
LithiumThe risk or severity of adverse effects can be increased when Cocaine is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Cocaine is combined with Lofentanil.
LomustineThe metabolism of Lomustine can be decreased when combined with Cocaine.
LoperamideThe metabolism of Loperamide can be decreased when combined with Cocaine.
LopinavirThe metabolism of Cocaine can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Cocaine is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Cocaine.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Cocaine.
LovastatinThe metabolism of Cocaine can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Cocaine.
Lu AA21004The risk or severity of adverse effects can be increased when Cocaine is combined with Lu AA21004.
LuliconazoleThe serum concentration of Cocaine can be increased when it is combined with Luliconazole.
LurasidoneThe risk or severity of adverse effects can be increased when Cocaine is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Cocaine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Cocaine is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Cocaine is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Cocaine is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Cocaine is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Cocaine is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Cocaine is combined with Melperone.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Cocaine.
MepivacaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Cocaine.
MequitazineThe serum concentration of Mequitazine can be increased when it is combined with Cocaine.
MesoridazineThe risk or severity of adverse effects can be increased when Cocaine is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Cocaine is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Cocaine.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Cocaine is combined with Methadyl Acetate.
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Cocaine.
MethapyrileneThe risk or severity of adverse effects can be increased when Cocaine is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Cocaine is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Cocaine is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Cocaine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Cocaine is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Cocaine is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Cocaine is combined with Methsuximide.
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Cocaine.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Cocaine.
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Cocaine.
MetoclopramideThe metabolism of Metoclopramide can be decreased when combined with Cocaine.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Cocaine.
MetyrosineCocaine may increase the sedative activities of Metyrosine.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Cocaine.
MianserinThe metabolism of Mianserin can be decreased when combined with Cocaine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Cocaine.
MifepristoneThe metabolism of Cocaine can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Cocaine is combined with Milnacipran.
MinaprineThe metabolism of Minaprine can be decreased when combined with Cocaine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Cocaine.
MirabegronThe metabolism of Mirabegron can be decreased when combined with Cocaine.
MirtazapineCocaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Cocaine.
MitotaneThe serum concentration of Cocaine can be decreased when it is combined with Mitotane.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Cocaine.
ModafinilThe serum concentration of Cocaine can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Cocaine is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Cocaine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Cocaine.
NabiloneCocaine may increase the tachycardic activities of Nabilone.
NafcillinThe serum concentration of Cocaine can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Cocaine.
NateglinideThe metabolism of Nateglinide can be decreased when combined with Cocaine.
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Cocaine.
NefazodoneThe metabolism of Cocaine can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Cocaine can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Cocaine can be increased when it is combined with Netupitant.
NetupitantThe metabolism of Netupitant can be decreased when combined with Cocaine.
NevirapineThe metabolism of Cocaine can be decreased when combined with Nevirapine.
NicardipineThe metabolism of Nicardipine can be decreased when combined with Cocaine.
NicergolineThe metabolism of Nicergoline can be decreased when combined with Cocaine.
NicotineThe metabolism of Nicotine can be decreased when combined with Cocaine.
NifedipineThe metabolism of Nifedipine can be decreased when combined with Cocaine.
NilotinibThe metabolism of Cocaine can be decreased when combined with Nilotinib.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Cocaine.
NitrazepamThe risk or severity of adverse effects can be increased when Cocaine is combined with Nitrazepam.
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Cocaine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Cocaine is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Cocaine is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Cocaine is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Cocaine is combined with Olanzapine.
OlaparibThe metabolism of Cocaine can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Cocaine is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Cocaine.
OpiumThe risk or severity of adverse effects can be increased when Cocaine is combined with Opium.
OrphenadrineCocaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Cocaine.
OsanetantThe risk or severity of adverse effects can be increased when Cocaine is combined with Osanetant.
OsimertinibThe serum concentration of Cocaine can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Cocaine.
OxprenololThe risk or severity of adverse effects can be increased when Cocaine is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Cocaine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Cocaine.
OxymorphoneThe risk or severity of adverse effects can be increased when Cocaine is combined with Oxymorphone.
PalbociclibThe serum concentration of Cocaine can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Cocaine is combined with Paliperidone.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Cocaine.
ParaldehydeCocaine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Cocaine.
ParoxetineThe risk or severity of adverse effects can be increased when Cocaine is combined with Paroxetine.
PazopanibThe metabolism of Pazopanib can be decreased when combined with Cocaine.
PentamidineThe metabolism of Pentamidine can be decreased when combined with Cocaine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Cocaine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Cocaine.
PerampanelThe risk or severity of adverse effects can be increased when Cocaine is combined with Perampanel.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Cocaine.
PerospironeThe risk or severity of adverse effects can be increased when Cocaine is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Cocaine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Cocaine.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Cocaine.
PhenforminThe metabolism of Phenformin can be decreased when combined with Cocaine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Cocaine is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Cocaine is combined with Phenoxyethanol.
PhenytoinThe risk or severity of adverse effects can be increased when Cocaine is combined with Phenytoin.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Cocaine.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Cocaine.
PindololThe metabolism of Pindolol can be decreased when combined with Cocaine.
PipamperoneThe risk or severity of adverse effects can be increased when Cocaine is combined with Pipamperone.
PiperazineThe metabolism of Piperazine can be decreased when combined with Cocaine.
PipotiazineThe risk or severity of adverse effects can be increased when Cocaine is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Cocaine is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Cocaine is combined with Pomalidomide.
PonatinibThe metabolism of Ponatinib can be decreased when combined with Cocaine.
PosaconazoleThe metabolism of Cocaine can be decreased when combined with Posaconazole.
PramipexoleCocaine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Cocaine is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Cocaine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Cocaine.
PrimidoneThe risk or severity of adverse effects can be increased when Cocaine is combined with Primidone.
ProcainamideThe metabolism of Procainamide can be decreased when combined with Cocaine.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Cocaine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Cocaine.
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Cocaine.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Cocaine.
PromethazineThe risk or severity of adverse effects can be increased when Cocaine is combined with Promethazine.
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Cocaine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Cocaine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Cocaine.
PropoxycaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Propoxycaine.
PropranololThe metabolism of Propranolol can be decreased when combined with Cocaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Cocaine is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Cocaine is combined with PSD502.
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Cocaine.
QuazepamThe risk or severity of adverse effects can be increased when Cocaine is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Cocaine is combined with Quetiapine.
QuinineThe metabolism of Quinine can be decreased when combined with Cocaine.
RamelteonThe risk or severity of adverse effects can be increased when Cocaine is combined with Ramelteon.
RanitidineThe metabolism of Ranitidine can be decreased when combined with Cocaine.
RanolazineThe metabolism of Cocaine can be decreased when combined with Ranolazine.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Cocaine.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Cocaine.
repinotanThe metabolism of repinotan can be decreased when combined with Cocaine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Cocaine.
RifabutinThe metabolism of Cocaine can be increased when combined with Rifabutin.
RifampicinThe metabolism of Cocaine can be increased when combined with Rifampicin.
RifapentineThe metabolism of Cocaine can be increased when combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Cocaine.
RitonavirThe metabolism of Cocaine can be decreased when combined with Ritonavir.
RomifidineThe risk or severity of adverse effects can be increased when Cocaine is combined with Romifidine.
RopiniroleCocaine may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Cocaine.
RotigotineCocaine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Cocaine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Cocaine is combined with S-Ethylisothiourea.
SaquinavirThe metabolism of Cocaine can be decreased when combined with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Cocaine is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Cocaine.
SertindoleThe risk or severity of adverse effects can be increased when Cocaine is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Cocaine is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Cocaine is combined with Sevoflurane.
SildenafilThe metabolism of Cocaine can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Cocaine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Cocaine can be increased when it is combined with Simeprevir.
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Cocaine.
Sodium oxybateThe risk or severity of adverse effects can be increased when Cocaine is combined with Sodium oxybate.
SparteineThe metabolism of Sparteine can be decreased when combined with Cocaine.
St. John's WortThe serum concentration of Cocaine can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Cocaine is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Cocaine.
SulfisoxazoleThe metabolism of Cocaine can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Cocaine.
SuvorexantThe risk or severity of adverse effects can be increased when Cocaine is combined with Suvorexant.
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Cocaine resulting in a loss in efficacy.
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Cocaine.
TapentadolThe risk or severity of adverse effects can be increased when Cocaine is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Cocaine is combined with Tasimelteon.
Technetium Tc-99m tilmanoceptCocaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.
TegaserodThe metabolism of Tegaserod can be decreased when combined with Cocaine.
TelaprevirThe metabolism of Cocaine can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Cocaine can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Cocaine.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Cocaine.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Cocaine.
TetrabenazineThe risk or severity of adverse effects can be increased when Cocaine is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Cocaine is combined with Tetrodotoxin.
ThalidomideCocaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Cocaine.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Cocaine.
ThiamylalThe risk or severity of adverse effects can be increased when Cocaine is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Cocaine.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Cocaine.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Cocaine.
ThiothixeneThe risk or severity of adverse effects can be increased when Cocaine is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Cocaine is combined with Tiagabine.
TiclopidineThe metabolism of Cocaine can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Cocaine is combined with Tiletamine.
TimololThe metabolism of Timolol can be decreased when combined with Cocaine.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Cocaine.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Cocaine.
TizanidineThe risk or severity of adverse effects can be increased when Cocaine is combined with Tizanidine.
TocilizumabThe serum concentration of Cocaine can be decreased when it is combined with Tocilizumab.
TolcaponeThe risk or severity of adverse effects can be increased when Cocaine is combined with Tolcapone.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Cocaine.
TopiramateThe risk or severity of adverse effects can be increased when Cocaine is combined with Topiramate.
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Cocaine.
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Cocaine.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Cocaine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Cocaine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Cocaine.
TrazodoneThe risk or severity of adverse effects can be increased when Cocaine is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Cocaine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Cocaine.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Cocaine.
TrimipramineThe risk or severity of adverse effects can be increased when Cocaine is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Cocaine is combined with Triprolidine.
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Cocaine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Cocaine.
VenlafaxineThe metabolism of Cocaine can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Cocaine can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Cocaine is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Cocaine is combined with Vilazodone.
VinblastineThe metabolism of Vinblastine can be decreased when combined with Cocaine.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Cocaine.
VoriconazoleThe metabolism of Cocaine can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Cocaine is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Cocaine is combined with Xylazine.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Cocaine.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Cocaine.
ZaleplonThe risk or severity of adverse effects can be increased when Cocaine is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Cocaine is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Cocaine is combined with Zimelidine.
ZiprasidoneThe metabolism of Cocaine can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Cocaine is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Cocaine is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Cocaine.
ZonisamideThe risk or severity of adverse effects can be increased when Cocaine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Cocaine is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Cocaine is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Cocaine is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A3
Uniprot ID:
Q01959
Molecular Weight:
68494.255 Da
References
  1. Wilson JM, Levey AI, Bergeron C, Kalasinsky K, Ang L, Peretti F, Adams VI, Smialek J, Anderson WR, Shannak K, Deck J, Niznik HB, Kish SJ: Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users. Ann Neurol. 1996 Sep;40(3):428-39. [PubMed:8797532 ]
  2. Kim DI, Schweri MM, Deutsch HM: Synthesis and pharmacology of site specific cocaine abuse treatment agents: 8-substituted isotropane (3-azabicyclo[3.2.1]octane) dopamine uptake inhibitors. J Med Chem. 2003 Apr 10;46(8):1456-64. [PubMed:12672245 ]
  3. Rothman RB, Baumann MH, Dersch CM, Appel J, Houghten RA: Discovery of novel peptidic dopamine transporter ligands by screening a positional scanning combinatorial hexapeptide library. Synapse. 1999 Sep 1;33(3):239-46. [PubMed:10420171 ]
  4. Carrera MR, Meijler MM, Janda KD: Cocaine pharmacology and current pharmacotherapies for its abuse. Bioorg Med Chem. 2004 Oct 1;12(19):5019-30. [PubMed:15351386 ]
  5. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Galli A, DeFelice LJ, Duke BJ, Moore KR, Blakely RD: Sodium-dependent norepinephrine-induced currents in norepinephrine-transporter-transfected HEK-293 cells blocked by cocaine and antidepressants. J Exp Biol. 1995 Oct;198(Pt 10):2197-212. [PubMed:7500004 ]
  2. Burchett SA, Bannon MJ: Serotonin, dopamine and norepinephrine transporter mRNAs: heterogeneity of distribution and response to 'binge' cocaine administration. Brain Res Mol Brain Res. 1997 Oct 3;49(1-2):95-102. [PubMed:9387868 ]
  3. Zhao Y, Sun L: Perinatal cocaine exposure reduces myocardial norepinephrine transporter function in the neonatal rat. Neurotoxicol Teratol. 2004 May-Jun;26(3):443-50. [PubMed:15113605 ]
  4. Carrera MR, Meijler MM, Janda KD: Cocaine pharmacology and current pharmacotherapies for its abuse. Bioorg Med Chem. 2004 Oct 1;12(19):5019-30. [PubMed:15351386 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Patkar AA, Berrettini WH, Hoehe M, Thornton CC, Gottheil E, Hill K, Weinstein SP: Serotonin transporter polymorphisms and measures of impulsivity, aggression, and sensation seeking among African-American cocaine-dependent individuals. Psychiatry Res. 2002 Jun 1;110(2):103-15. [PubMed:12057823 ]
  2. Barker EL, Moore KR, Rakhshan F, Blakely RD: Transmembrane domain I contributes to the permeation pathway for serotonin and ions in the serotonin transporter. J Neurosci. 1999 Jun 15;19(12):4705-17. [PubMed:10366604 ]
  3. Corey JL, Quick MW, Davidson N, Lester HA, Guastella J: A cocaine-sensitive Drosophila serotonin transporter: cloning, expression, and electrophysiological characterization. Proc Natl Acad Sci U S A. 1994 Feb 1;91(3):1188-92. [PubMed:8302852 ]
  4. Carrera MR, Meijler MM, Janda KD: Cocaine pharmacology and current pharmacotherapies for its abuse. Bioorg Med Chem. 2004 Oct 1;12(19):5019-30. [PubMed:15351386 ]
  5. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated sodium channel activity involved in sa node cell action potential
Specific Function:
This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient. It is a tetrodotoxin-resistant Na(+) channel isoform. This channel is respon...
Gene Name:
SCN5A
Uniprot ID:
Q14524
Molecular Weight:
226937.475 Da
References
  1. Antzelevitch C: Brugada syndrome. Pacing Clin Electrophysiol. 2006 Oct;29(10):1130-59. [PubMed:17038146 ]
  2. Satish OS, Yeh KH, Wen MS: Brugada syndrome--an update. Chang Gung Med J. 2005 Feb;28(2):69-76. [PubMed:15880981 ]
  3. Wright SN, Wang SY, Xiao YF, Wang GK: State-dependent cocaine block of sodium channel isoforms, chimeras, and channels coexpressed with the beta1 subunit. Biophys J. 1999 Jan;76(1 Pt 1):233-45. [PubMed:9876137 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated sodium channel activity
Specific Function:
This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which sodium ions may pass in accordance with their electrochemical gradient. It is a tetrodotoxin-resistant sodium channel isoform. Also involved, with ...
Gene Name:
SCN11A
Uniprot ID:
Q9UI33
Molecular Weight:
204919.66 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated sodium channel activity
Specific Function:
Tetrodotoxin-resistant channel that mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which sodium ions may pass in accordance with their electrochemical gradient. Plays a role in neuropathic pain mechanisms.
Gene Name:
SCN10A
Uniprot ID:
Q9Y5Y9
Molecular Weight:
220623.605 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Carrera MR, Meijler MM, Janda KD: Cocaine pharmacology and current pharmacotherapies for its abuse. Bioorg Med Chem. 2004 Oct 1;12(19):5019-30. [PubMed:15351386 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Carrera MR, Meijler MM, Janda KD: Cocaine pharmacology and current pharmacotherapies for its abuse. Bioorg Med Chem. 2004 Oct 1;12(19):5019-30. [PubMed:15351386 ]
  2. Sharkey J, Ritz MC, Schenden JA, Hanson RC, Kuhar MJ: Cocaine inhibits muscarinic cholinergic receptors in heart and brain. J Pharmacol Exp Ther. 1988 Sep;246(3):1048-52. [PubMed:3047364 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Ladona MG, Gonzalez ML, Rane A, Peter RM, de la Torre R: Cocaine metabolism in human fetal and adult liver microsomes is related to cytochrome P450 3A expression. Life Sci. 2000 Dec 15;68(4):431-43. [PubMed:11205892 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Quaternary ammonium group transmembrane transporter activity
Specific Function:
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creatinine, amantadine, memantine, acriflavine, 4-[4-(dimethylamino)-styryl]-N-methylpyridinium ASP, amiloride, metformin, N-1-methylnicotinamide (NMN), tetraethylammonium (TEA), 1-methyl-4-phenylpyridiniu...
Gene Name:
SLC22A2
Uniprot ID:
O15244
Molecular Weight:
62579.99 Da
References
  1. Grundemann D, Koster S, Kiefer N, Breidert T, Engelhardt M, Spitzenberger F, Obermuller N, Schomig E: Transport of monoamine transmitters by the organic cation transporter type 2, OCT2. J Biol Chem. 1998 Nov 20;273(47):30915-20. [PubMed:9812985 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23